Literature DB >> 26654761

Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines.

Nadia Panera1, Claudia Della Corte2, Annalisa Crudele1, Laura Stronati3, Valerio Nobili2, Anna Alisi1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is currently considered the main cause of chronic liver disease worldwide. Mechanisms leading to the development and progression of this disease are topics of great interest for researchers and clinicians. The current multi-hit hypothesis has thrown the crosstalk between liver and adipose tissue into sharp focus. It is well known that adipose tissue produces circulating factors, known as adipocytokines, which exert several effects on liver cells, promoting the onset of NAFLD and its progression to non-alcoholic steatohepatitis in obese subjects. In a similar way, hepatocytes may also respond to obesogenic stimuli by producing and releasing hepatokines into the circulation. Here, the authors provide an overview of recent advances in our understanding of the role of the most relevant adipocytokines and hepatokines in NAFLD pathogenesis, highlighting their possible molecular and functional interactions.

Entities:  

Keywords:  Adipocytokines; FGF21; IL-6; NAFLD; TNF-α; adiponectin; fetuin-A; hepatokines; leptin; resistin

Mesh:

Substances:

Year:  2015        PMID: 26654761     DOI: 10.1586/17474124.2016.1110485

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  6 in total

Review 1.  Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future.

Authors:  João Paulo Margiotti Dos Santos; Mariana Canevari de Maio; Monike Alves Lemes; Lucas Fornari Laurindo; Jesselina Francisco Dos Santos Haber; Marcelo Dib Bechara; Pedro Sidnei do Prado; Eduardo Costa Rauen; Fernando Costa; Barbara Cristina de Abreu Pereira; Uri Adrian Prync Flato; Ricardo de Alvares Goulart; Eduardo Federighi Baisi Chagas; Sandra Maria Barbalho
Journal:  Int J Mol Sci       Date:  2022-01-02       Impact factor: 5.923

Review 2.  Stearoyl-CoA desaturase 1: A potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence.

Authors:  Shanmugam Murugaiha Jeyakumar; Ayyalasomayajula Vajreswari
Journal:  World J Hepatol       Date:  2022-01-27

3.  Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study.

Authors:  Shanshan Wu; Changzheng Yuan; Zhirong Yang; Si Liu; Qian Zhang; Shutian Zhang; Shengtao Zhu
Journal:  BMC Med       Date:  2022-08-22       Impact factor: 11.150

4.  Inflammatory Cytokines, Adipocytokines, and Th17/Treg Balance in Patients with Nonalcoholic Fatty Liver Disease following Administration of Dahuang Zhechong Pills.

Authors:  Xiaohua Duan; Jianlin Lv; Hebei Jiang; Kefei Zheng; Yulin Chen
Journal:  Genet Res (Camb)       Date:  2022-01-07       Impact factor: 1.588

5.  RvD1 Attenuated Susceptibility to Ischemic AKI in Diabetes by Downregulating Nuclear Factor-κ B Signal and Inhibiting Apoptosis.

Authors:  Zheng Li; Zhiwen Liu; Hengcheng Lu; Wenni Dai; Junxiang Chen; Liyu He
Journal:  Front Physiol       Date:  2021-07-13       Impact factor: 4.566

Review 6.  Adiponectin in psoriasis and its comorbidities: a review.

Authors:  Bai Ruiyang; Fu Siqi; Adriana Panayi; Wu Ruifang; Zhang Peng
Journal:  Lipids Health Dis       Date:  2021-08-09       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.